News Releases Keyword Search Year None2026202520242023202220212020201920182017201620152014 Aug 10, 2026 Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress Aug 03, 2026 Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease Jun 12, 2026 Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million May 28, 2026 Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences May 07, 2026 Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress Apr 28, 2026 Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher Mar 27, 2026 Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I) Feb 26, 2026 Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress Feb 23, 2026 Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences Jan 05, 2026 Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference Print Page RSS E-mail Alerts Contact
Keyword Search Year None2026202520242023202220212020201920182017201620152014 Aug 10, 2026 Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress Aug 03, 2026 Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease Jun 12, 2026 Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million May 28, 2026 Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences May 07, 2026 Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress Apr 28, 2026 Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher Mar 27, 2026 Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I) Feb 26, 2026 Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress Feb 23, 2026 Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences Jan 05, 2026 Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Aug 10, 2026 Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress
Aug 03, 2026 Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease
Jun 12, 2026 Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
May 07, 2026 Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress
Mar 27, 2026 Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)
Feb 26, 2026 Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress
Jan 05, 2026 Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference
